- Home
- CAVA vs MRNA Comparison
CAVA vs MRNA Comparison
Compare CAVA & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAVA | MRNA |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 61.6B |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CAVA | MRNA |
|---|---|---|
| Price | $53.31 | $188.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 12 |
| Target Price | ★ $91.00 | $34.27 |
| AVG Volume (30 Days) | 3.3M | ★ 12.9M |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 0.39 | N/A |
| Revenue | $1,179,664,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $25.71 | $9.36 |
| Revenue Next Year | $20.57 | $15.43 |
| P/E Ratio | $134.15 | ★ N/A |
| Revenue Growth | ★ 22.41 | 4.29 |
| 52 Week Low | $43.41 | $22.28 |
| 52 Week High | $98.79 | $208.90 |
Technical Indicators
Market Signals| Indicator | CAVA | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 35.98 | 75.87 |
| Support Level | $49.68 | $43.35 |
| Resistance Level | $55.41 | N/A |
| Average True Range (ATR) | 2.07 | 11.47 |
| MACD | 0.25 | 2.59 |
| Stochastic Oscillator | 40.23 | 86.71 |
Price Performance
Historical ComparisonAbout CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It operates a Mediterranean-inspired fast-casual restaurant brand offering menu items. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: i) CAVA: It includes the operations of all company-owned CAVA restaurants, and ii) CAVA Foods: It includes the production of dips, spreads, and certain dressing bases used in CAVA restaurants as well as sales from the Company's consumer packaged goods business. The company generates the majority of its revenue from the CAVA segment.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.